Filing Flows › GeneDx Holdings (WGS) › Q3 2026
GeneDx Holdings (WGS) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 9, 2026
GeneDx Holdings (WGS) reported revenue of $123M for the third quarter 2026 (Q3 2026), +5% from a year earlier and +8% from the quarter before. Operating margin was -8.5%, net loss $12.3M (10.0% of revenue).
GeneDx Holdings, Q3 2026: revenue $123M (+5% year over year), operating margin -8.5%, net loss $12.3M, operating cash flow −$10.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $123M | +8% | +5% |
| Operating profit | −$10.4M | — | — |
| Net earnings | −$12.3M | — | — |
| Operating cash flow | −$10.6M | — | -167% |
What changed
Revenue was $123.1M in Q3 2026, up 5% year over year and up 8% from the previous quarter. Patients with third-party insurance was the largest line at 84% of revenue. Patients with third-party insurance added $8.9M year over year (up 9%), 139% of the total change. Institutional customers declined 10%.
Gross margin was 69.9%, down 2.5 points from Q3 2025. Operating costs exceeded revenue by $10.4M, an operating margin of -8.5%. Operating expenses grew 10% against revenue growth of 5%. The quarter ended with a net loss of $12.3M, narrower than the previous quarter's $17.7M loss.
Operating cash flow was −$10.6M. Non-cash charges added back $6.9M of depreciation and amortization and $8.3M of share-based compensation. Working capital and other items used $13.4M.
Questions
What was GeneDx Holdings' revenue in the third quarter 2026?
GeneDx Holdings (WGS) reported revenue of $123M for the third quarter 2026 (Q3 2026), +5% from a year earlier and +8% from the quarter before.
Was GeneDx Holdings profitable in the third quarter 2026?
Operating loss was $10.4M (-8.5% of revenue) and net loss $12.3M.
Source: GeneDx Holdings 10-Q on SEC EDGAR.